SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has launched an underwritten public offering of $400.0 million of its common stock. In connection with the Offering, Catalent intends to grant the underwriters an option for 30 days to purchase up to $60.0 million of additional shares of its common stock.

Catalent intends to use the net proceeds of the Offering to repay a portion of the outstanding borrowings under its U.S. dollar-denominated term loans.

J.P. Morgan, Morgan Stanley, RBC Capital Markets, BofA Merrill Lynch and Wells Fargo Securities are acting as bookrunners for the Offering.